David Sher, Vice Chair of Clinical Operations and Quality, Medical Director of Radiation Oncology, Chief of Head and Neck Radiation Oncology Service at UTSW Medical Center, shared a post on X:
“It’s very exciting to see the final results of the US phase III RCT of IMPT versus IMRT for oropharyngeal squamous cell carcinoma.
Data have been percolating for some time at conferences (and social media), and it’s great to be able to crunch through the actual paper.
I think our community owes a debt of gratitude to the investigators for pulling this trial off. It takes passion, perseverance and just raw time and effort to make such a study happen, and the resultant information is really valuable.
There is a lot to go through here, I’ll start with my final conclusion, which is that IMPT is A, but not THE, standard-of-care for oropharyngeal cancer”
Title: Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Authors: Prof Steven J Frank, Prof Paul M Busse, Prof J Jack Lee, Prof David I Rosenthal, Mike Hernandez, David M Swanson, Prof Adam S Garden, Prof G Brandon Gunn, Prof Samir H Patel, James W Snider, Prof Daniel J Ma, Jason K Molitoris, Nancy Y Lee, Prof Upendra Parvathaneni, Prof Mark W McDonald, Noah S Kalman, Prof Alexander Lin, Nasiruddin Mohammed, Christina Henson, Christian Hyde, Gopal K Bajaj, Sanford R Katz, Roi Dagan, Prof William H Morrison, Jay P Reddy, Prof C David Fuller, Prof Shalin J Shah, Prof Jack Phan, Prof Gregory M Chronowski, Lauren Mayo, Prof Erich M Sturgis, Prof Renata Ferrarotto, Prof Xiaorong R Zhu, Prof Xiaodong Zhang, Li Wang, Prof Katherine A Hutcheson, Prof Adel K El-Naggar, Amy C Moreno, Anna Lee, Michael T Spiotto, Prof Neil D Gross, Prof Stephen Y Lai, Jay J Liao, Jonathan Paly, Prof Zhongxing Liao, Prof Robert L Foote
You can read the full article in The Lancet.
More posts featuring David Sher on OncoDaily.